You may worry that this will bring you too high. If you take insulin, this poses no problem. Simply check your blood sugar when you get back to your meter. If it ’s above your target, take enough lispro (or aspart or glulisine) to bring you back to target, but be sure to wait 5 hours after your last dose of rapid-acting insulin. If you don’t take insulin, your blood sugar should eventually come back on its own, because your pancreas is still making some insulin. It may take several hours, or even a day, depending upon how rapidly you can produce insulin. In any event, you may have saved yourself an embarrassing or even disastrous situation.
*This offer is only valid for patients with commercial insurance. Eligible uninsured patients will pay more. This offer is not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state, or other governmental programs, including, but not limited to, Medicare (including Medicare Advantage and Part A, B, and D plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan, or any other federal or state health care programs. This offer is good only in the United States of America (including the District of Columbia, Puerto Rico and the . Virgin Islands) at retail pharmacies owned and operated by Walgreen Co. (or its affiliates) and other participating independent retail pharmacies. This offer is not valid in Massachusetts or Minnesota or where otherwise prohibited, taxed, or otherwise restricted. This offer is not valid for redemption in the State of California or by any resident of the State of California with regard to any product for which a therapeutically equivalent generic product is available, including but not limited to Locoid lotion, Loprox shampoo, some strengths of Solodyn , and Ziana . Click here for other terms and conditions that apply.
A 24-week, double-blind, placebo-controlled trial of immediate release metformin plus insulin versus insulin plus placebo was conducted in patients with type 2 diabetes who failed to achieve adequate glycemic control on insulin alone. Patients randomized to receive metformin plus insulin achieved a mean reduction in HbA1c of %, compared to a % reduction in HbA1c achieved by insulin plus placebo. The improvement in glycemic control was achieved at the final study visit with 16% less insulin, 93 U/day vs. U/day, metformin plus insulin versus insulin plus placebo, respectively, p=.
A second double-blind, placebo-controlled study (n=51), with 16 weeks of randomized treatment, demonstrated that in patients with type 2 diabetes controlled on insulin for 8 weeks with an average HbA1c of ± %, the addition of metformin maintained similar glycemic control (HbA1c ± versus ± for metformin plus insulin and placebo plus insulin, respectively) with 19% less insulin versus baseline (reduction of ± versus an increase of ± units for metformin plus insulin and placebo plus insulin, p<). In addition, this study demonstrated that the combination of metformin plus insulin resulted in reduction in body weight of ± lbs, compared to an increase of ± lbs for placebo plus insulin, p=.